An Open-Label, Single and Multiple-Ascending Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Subjects

Condition:   Pulmonary Disease, Chronic Obstructive Interventions:   Drug: Aclidinium Bromide 200 μg;   Drug: Aclidinium Bromide 400 μg;   Drug: Aclidinium Bromide 800 μg Sponsor:   AstraZeneca Not yet recruiting - verified August 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials